Peer-reviewed Publications

Champions Oncology Authored Publications

Oncotarget: Volasertib preclinical activity in high-risk hepatoblastoma

November 2019

Download Publication

Sci Signal: The HDAC3-SMARCA4-miR27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma

May 2019

Download Publication

Cancer Research: PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

November 2017

Download Publication

British Journal of Cancer: Comparative mutational landscape analysis of patient-derived tumour xenografts

January 2017

Download Publication

Clinical Cancer Research: Screening of conditionally reprogrammed patient-derived carcinoma cells identified ERCC3-MYC interactions as a target in pancreatic cancer

December 2016

Download Publication

Cancer: Patient-derived xenografts for individualized care in advanced sarcoma

July 2014

Download Publication

Clinical Cancer Research: Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

May 2014

Download Publication

Journal of Clinical Oncology: Prioritizing phase I treatment options through preclinical testing on personalized TumorGraft

February 2012

Download Publication

Publications Using Champions Oncology’s TumorGraft Models

Molecular Cancer Therapeutics: Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

April 2020

Download Publication

Molecular Cancer Therapeutics: ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

February 2020

Download Publication

Breast Cancer Research: Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

December 2019

Download Publication

Nature Communications: AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

November 2019

Download Publication

Nature Communications: The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

August 2019

Download Publication